{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:30:39Z","timestamp":1761093039282,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.urolonc.2021.08.019","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T02:44:25Z","timestamp":1634611465000},"page":"109.e1-109.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Differences in genomic profile of high-grade urothelial carcinoma according to tumor location"],"prefix":"10.1016","volume":"40","author":[{"given":"Cheol Keun","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam Hoon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2021.08.019_bib0001","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0002","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update","volume":"79","author":"Roupr\u00eat","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0003","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0004","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1016\/j.ejca.2009.06.016","article-title":"Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients","volume":"45","author":"Lughezzani","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0005","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1002\/cncr.25122","article-title":"Highly predictive survival nomogram after upper urinary tract urothelial carcinoma","volume":"116","author":"Jeldres","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0006","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.urolonc.2019.05.020","article-title":"How cancer-specific mortality changes over time after radical cystectomy: conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder","volume":"37","author":"Palumbo","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0007","doi-asserted-by":"crossref","unstructured":"Alfred Witjes J, Lebret T, Comp\u00e9rat EM, Cowan NC, De Santis M, Bruins HM,\u00a0 et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2017;71:462-75.","DOI":"10.1016\/j.eururo.2016.06.020"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0008","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.eururo.2020.05.039","article-title":"Molecular characterization of upper tract urothelial carcinoma in the Era of next-generation sequencing: a systematic review of the current literature","volume":"78","author":"Hassler","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0009","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0011","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0012","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","article-title":"Comprehensive genomic characterization of upper tract urothelial carcinoma","volume":"72","author":"Moss","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0013","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.tranon.2017.10.008","article-title":"Molecular characterization of urothelial carcinoma of the bladder and upper urinary tract","volume":"11","author":"Lee","year":"2018","journal-title":"Transl Oncol"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0014","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4143\/crt.2019.305","article-title":"Detection of targetable genetic alterations in korean lung cancer patients: a comparison study of single-gene assays and targeted next-generation sequencing","volume":"52","author":"Park","year":"2020","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0015","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jtho.2019.07.006","article-title":"Spatial and temporal heterogeneity of panel-based tumor mutational burden in pulmonary adenocarcinoma: separating biology from technical artifacts","volume":"14","author":"Kazdal","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0016","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0017","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0018","doi-asserted-by":"crossref","DOI":"10.4143\/crt.2021.031","article-title":"Ferroportin and FBXL5 as prognostic markers in advanced stage clear cell renal cell carcinoma","author":"Park","year":"2021","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0019","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/PAS.0000000000001084","article-title":"PD-L1 immunohistochemistry assay concordance in urothelial carcinoma of the bladder and hypopharyngeal squamous cell carcinoma","volume":"42","author":"Hodgson","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0020","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0021","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0022","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0023","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1078-0432.CCR-18-2039","article-title":"Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma","volume":"25","author":"Audenet","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0024","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/cam4.262","article-title":"FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder","volume":"3","author":"Guancial","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005214","article-title":"FGFR3 deficiency causes multiple chondroma-like lesions by upregulating hedgehog signaling","volume":"11","author":"Zhou","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0026","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2147\/OTT.S34678","article-title":"Targeting hedgehog signaling in cancer: research and clinical developments","volume":"6","author":"Xie","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0027","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0028","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc4220","article-title":"ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC","volume":"12","author":"Goswami","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0029","first-page":"1643","article-title":"Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer","volume":"3","author":"Newby","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/187152211795495643","article-title":"Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block","volume":"11","author":"Jathal","year":"2011","journal-title":"Immunol Endocr Metab Agents Med Chem"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0031","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ccr.2011.10.006","article-title":"Resistance to EGFR-targeted therapy: a family affair","volume":"20","author":"Vlacich","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0032","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.yexcr.2010.01.009","article-title":"Mechanisms of resistance to HER family targeting antibodies","volume":"316","author":"Kruser","year":"2010","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0033","first-page":"355","article-title":"HER3 signaling and targeted therapy in cancer","volume":"12","author":"Mishra","year":"2018","journal-title":"Oncol Rev"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0034","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1158\/0008-5472.CAN-12-1611","article-title":"Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0035","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00280-011-1806-6","article-title":"Preclinical pharmacokinetics of MEHD7945A, a novel EGFR\/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose","volume":"69","author":"Kamath","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0036","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0037","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2021.08.019_bib0038","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/cncr.31314","article-title":"Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA","volume":"124","author":"Agarwal","year":"2018","journal-title":"Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921003847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921003847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:23:33Z","timestamp":1761042213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921003847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1078143921003847"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.08.019","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in genomic profile of high-grade urothelial carcinoma according to tumor location","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}